Linked Life Data

6084216

Source:http://linkedlifedata.com/resource/pubmed/id/6084216

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1985-3-15
pubmed:abstractText
In a retrospective study, 2688 eyes treated with xenon arc photocoagulation which would have qualified for inclusion in the Diabetic Retinopathy Study (DRS) were reviewed in the format of the DRS. When comparable risk groups were compared, the results of treatment were even more favorable than reported in the DRS without the severe complications attributed to xenon treatment in the DRS. A critical analysis of the DRS gives clues for the greater amount of visual loss found with xenon than argon in the DRS. Since these complications may be avoidable in some cases, and since xenon has been shown to be at least as effective as argon, it should continue to be used in the treatment of proliferative diabetic retinopathy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0161-6420
pubmed:author
pubmed:issnType
Print
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1458-63
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Xenon arc photocoagulation of proliferative diabetic retinopathy. A review of 2688 consecutive eyes in the format of the Diabetic Retinopathy Study.
pubmed:publicationType
Journal Article, Comparative Study